A Phase I, open label, dose escalation trial of LH031 (4SC-205) in adult patients with advanced solid malignancies or lymphoma
Latest Information Update: 06 Jan 2021
At a glance
- Drugs 4SC 205 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Link Health Group
Most Recent Events
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 14 Aug 2019 New trial record